Taweh Beysolow, MD
Nephrology · Key West, FLNPI 1720065212
Payments from drug & device makers
Across 125 payments — averaging $103.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$9K
- AstraZeneca$449
- Bayer$395
- Baxter Healthcare$390
- Amgen$281
- Mallinckrodt Hospital Products Inc.$271
- plus $2K from 28 others
What the payments were for
- Consulting fees$8,20064%
- Food & beverage$4,57135%
- Education$1151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 12 | $8,638 |
| AstraZeneca(2 entities) | 13 | $449 |
| Bayer | 11 | $395 |
| Baxter Healthcare | 5 | $390 |
| Amgen(2 entities) | 4 | $281 |
| Mallinckrodt Hospital Products Inc. | 11 | $271 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $270 |
| Mallinckrodt Enterprises LLC | 2 | $222 |
| Novo Nordisk | 5 | $212 |
| Nxstage Medical, Inc. | 3 | $203 |
| Abiomed | 3 | $195 |
| Otsuka America Pharmaceutical, Inc. | 11 | $186 |
| Medtronic | 1 | $139 |
| Veloxis Pharmaceuticals, Inc. | 1 | $124 |
| Akebia Therapeutics Inc | 7 | $110 |
| ANI Pharmaceuticals, Inc. | 4 | $96 |
| Abbott | 1 | $89 |
| Boston Scientific | 1 | $87 |
| Lilly USA, LLC | 3 | $54 |
| Merck | 2 | $51 |
| GSK | 2 | $48 |
| Travere Therapeutics, Inc. | 2 | $47 |
| Aurinia Pharma U.S., Inc. | 2 | $46 |
| Vifor Pharma, Inc. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| OPKO Pharmaceuticals, LLC | 1 | $33 |
| Johnson & Johnson | 2 | $27 |
| Boehringer Ingelheim | 2 | $26 |
| Ardelyx, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Pfizer | 1 | $18 |
| Novartis | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$8,426
- Envarsus$248
- KRYSTEXXA$239
- SYMPLICITY G3$139
- Renal - Acute$128
- Kerendia$125
- ACTHAR$122
How this compares
$12,886 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 213 | $186,952 |
| OzempicSemaglutide | 139 | $163,599 |
| VelphoroSucroferric Oxyhydroxide | 37 | $95,124 |
| EliquisApixaban | 78 | $90,792 |
| TrulicityDulaglutide | 59 | $76,088 |
| MounjaroTirzepatide | 51 | $70,686 |
| EntrestoSacubitril/Valsartan | 51 | $67,579 |
| FarxigaDapagliflozin Propanediol | 65 | $60,189 |
| RybelsusSemaglutide | 29 | $47,953 |
| VascepaIcosapent Ethyl | 87 | $39,036 |
| KerendiaFinerenone | 27 | $35,054 |
| JanuviaSitagliptin Phosphate | 19 | $21,448 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $19,224 |
| AuryxiaFerric Citrate | 15 | $18,219 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $11,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $212 | $211,552168 claims |
| Boehringer IngelheimJardiance | $26 | $186,952213 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $54 | $146,775110 claims |
| PfizerEliquis | $18 | $90,79278 claims |
| AstraZenecaFarxiga, Lokelma | $449 | $79,41388 claims |
| NovartisEntresto | $14 | $67,57951 claims |
| BayerKerendia | $395 | $35,05427 claims |
| MerckJanuvia, Janumet | $51 | $33,25930 claims |
| Akebia Therapeutics IncAuryxia | $110 | $18,21915 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $48 | $13,31624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.
Other nephrology in Key West
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.